Therapy Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Therapy Name Anetumab ravtansine
Synonyms
Therapy Description

Anetumab ravtansine is a monoclonal antibody against mesothelin (MSLN) in conjugation with maytansinoid DM4, which delivers maytansinoid DM4 to tumor cells over expressing mesothelin, resulting in tumor cell death (PMID: 24714131).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Anetumab ravtansine BAY94-9343|BAY 94-9343 MSLN Antibody 5 Anetumab ravtansine (BAY94-9343) is a monoclonal antibody against mesothelin (MSLN) in conjugation with maytansinoid DM4, which delivers maytansinoid DM4 to tumor cells over expressing mesothelin, resulting in tumor cell death (PMID: 24714131, PMID: 32815024, PMID: 32213105).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown Advanced Solid Tumor not applicable Anetumab ravtansine Phase I Actionable In a Phase I trial, Anetumab ravtansine (BAY94-9343) treatment demonstrated safety and resulted in one complete response, 11 partial responses, and 66 stable disease in patients with advanced solid tumors (n=148), 11 of the responses occurred in mesothelioma or ovarian cancer patients with over 30% of tumor cells expressing MSLN (mesothelin) (2+ or 3+ by IHC) (PMID: 32213105; NCT03102320). 32213105

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT03023722 Phase II Anetumab ravtansine Phase II Anetumab Ravtansine as 2nd Line Treatment for Pancreatic Cancer Completed USA 0
NCT02839681 Phase II Anetumab ravtansine Anti-Mesothelin Antibody Drug Conjugate Anetumab Ravtansine for Mesothelin Expressing Lung Adenocarcinoma Terminated USA 0
NCT03926143 Phase II Anetumab ravtansine A Clinical Study of Anetumab Ravtansine in Adults With Solid Tumors Who Have Been Treated in Previous Bayer-sponsored Anetumab Ravtansine Studies Enrolling by invitation USA 3
NCT03102320 Phase I Anetumab ravtansine Anetumab ravtansine + Gemcitabine Anetumab ravtansine + Cisplatin Phase 1b Multi-indication Study of Anetumab Ravtansine in Mesothelin Expressing Advanced Solid Tumors (ARCS-Multi) Active, not recruiting USA | CAN 10
NCT02824042 Phase I Anetumab ravtansine + Itraconazole Anetumab ravtansine Thorough ECG (Electrocardiogram) and Drug Interaction Study With Anetumab Ravtansine and Itraconazole Completed USA 5


Additional content available in CKB BOOST